All Type of News
‘Fycompa’ turned in the registration of the health insurance benefit, giving an advance notice as a new mechanism of epilepsy treatment
A prescription option for a new mechanism of epilepsy treatment is going to be added.
According to the industry concerned on the 30th, Eisai has turned in a registration application of the health insurance benefit fo...
Hanmi Pharm established a $730 million worth license contract for an anticancer new drug with BoehringerHanmi Pharm(President Kwan-soon Lee) announced on the 28th that it established a license contract for its targeted lung cancer new drug(HM61713), which is being developed on its...
|
Boehringer replaces its head in 4 years with a new CEO appointed in October
Chief of Boehringer Ingelheim will be replaced in approximately 4 years.
According to the industry concerned on the 29th, CEO Dirk van Niekerk, who had led Boehringer Ingelheim Korea since May 2012, will leave the co...
Doctors from applicant hospitals are not allowed to participate in the deliberation committee for the super expensive drug, Soliris
Restriction is now placed for medical doctors the related hospital which applied for the insurance benefit of the paroxysmal nocturnal hemoglobinuria(PNH) treatment, Soliris Inj(eculizumab), not to be involved with vo...
The KRW 4 trillion hair loss market has leaked into shade while the government is not approving the DPCP treatment
While the government indicated the most effective treatment for severe hair loss patients, ‘DPCP(Diphenylcyclopropenone)’ as illegal, there is no regulation to control wrong folk remedies or beliefs; thus, a criticism...
Pharmaceutical and biopharmaceutical companies recorded the largest scale of IPOs ever in the first half of the year
It is estimated that the sizes of IPOs(Initial Public Offering) in the domestic healthcare industry will be the largest ever last year, approximately KRW 332.3 billion, increasing 142.8% up.
According to the NH Inves...
The ‘monopolistic’ brain tumor treatment ‘Temodal’ will face 3-way competition against domestic pharmaceutical products
As a domestic pharmaceutical company entered the MSD’s brain tumor treatment ‘Temodal(temozolomide)’ market, the 3-way competition is expected to be formed.
Temodal was expired in patent on December 2011, but has tak...
Pharmacists pay attention to the next pharmacy claim SW which will replace PM2000
“We will provide a new program with the highest security system which will make no damage to pharmacies using PM2000.”
This is a part of the statement of Chan-hui Jo, the president of the Korean Pharmaceutical Associ...
Novo and Sanofi expects to make fierce competition over the next term’s insulin
The strong of insulin are going to compete in its market for the next term. They have not been unveiled, but will be launched within this year to preoccupy the market.
According to the industry concerned on the 27th,...
Biosimilars closed to commercialization challenges against a multinational company
Domestic biosimilar development companies, highly anticipated to acquire approvals soon, are underway to nullify patents and launch their products early.
In order to launch their products early, Samsung Bioepis and ...
